HER2 (human epidermal growth factor receptor 2, or HER2/neu) is primarily used to identify likely responders to adjuvant trastuzumab therapy (Herceptin, Genentech Inc., San Francisco, California, USA) in breast and gastric cancer [45]. This evidence concerns the gene ERBB2 and gastric cancer.